Utilization of triple antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention

[1]  Seil Oh,et al.  Comparison of early clinical outcomes between dual antiplatelet therapy and triple antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention , 2022, PloS one.

[2]  N. Je,et al.  Underutilization of anticoagulants in patients with nonvalvular atrial fibrillation in the era of non-vitamin K antagonist oral anticoagulants , 2022, International Journal of Arrhythmia.

[3]  P. Bocchino,et al.  Atrial fibrillation and coronary artery disease: a review on the optimal use of oral anticoagulants. , 2021, Reviews in cardiovascular medicine.

[4]  Deepak L. Bhatt,et al.  Antithrombotic Therapy in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Undergoing Percutaneous Coronary Intervention: A North American Perspective: 2021 Update. , 2021, Circulation.

[5]  R. Mahfouz,et al.  The interplay between atrial fibrillation and acute myocardial infarction. , 2021, British journal of hospital medicine.

[6]  Jeroen J. Bax,et al.  2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS). , 2020, European heart journal.

[7]  Deepak L. Bhatt,et al.  2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. , 2020, European heart journal.

[8]  R. de Caterina,et al.  Optimal Antithrombotic Treatment of Patients with Atrial Fibrillation Early after an Acute Coronary Syndrome—Triple Therapy, Dual Antithrombotic Therapy with an Anticoagulant… Or, Rather, Temporary Dual Antiplatelet Therapy? , 2020, Journal of clinical medicine.

[9]  Sun-Young Jung,et al.  Conducting and Reporting a Clinical Research Using Korean Healthcare Claims Database , 2020, Korean journal of family medicine.

[10]  G. Lippi,et al.  Global epidemiology of atrial fibrillation: An increasing epidemic and public health challenge , 2020, International journal of stroke : official journal of the International Stroke Society.

[11]  J. Camm,et al.  Time‐trends and treatment gaps in the antithrombotic management of patients with atrial fibrillation after percutaneous coronary intervention: Insights from the CHUM AF‐STENT Registry , 2019, Clinical cardiology.

[12]  S. Niwano,et al.  Real-World Antithrombotic Therapy in Atrial Fibrillation Patients with a History of Percutaneous Coronary Intervention. , 2019, International heart journal.

[13]  N. Je,et al.  National trends in metformin-based combination therapy of oral hypoglycaemic agents for type 2 diabetes mellitus , 2019, European Journal of Clinical Pharmacology.

[14]  Hugh Calkins,et al.  2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. , 2019, Journal of the American College of Cardiology.

[15]  Seil Oh,et al.  Temporal trends in prevalence and antithrombotic treatment among Asians with atrial fibrillation undergoing percutaneous coronary intervention: A nationwide Korean population-based study , 2019, PloS one.

[16]  A. Camm,et al.  Time trends in antithrombotic management of patients with atrial fibrillation treated with coronary stents: Results from TALENT‐AF (The internAtionaL stENT – Atrial Fibrillation study) multicenter registry , 2018, Clinical cardiology.

[17]  J. Małyszko,et al.  Patients with atrial fibrillation and coronary artery disease - Double trouble. , 2018, Advances in medical sciences.

[18]  G. Lip,et al.  Antithrombotic Therapy for Atrial Fibrillation: CHEST Guideline and Expert Panel Report , 2012, Chest.

[19]  G. Lip,et al.  Bleeding Risk Scores in Atrial Fibrillation and Venous Thromboembolism. , 2017, The American journal of cardiology.

[20]  E. Kalaycıoğlu,et al.  Impact of valvular heart disease on oral anticoagulant therapy in non-valvular atrial fibrillation: results from the RAMSES study , 2017, Journal of Thrombosis and Thrombolysis.

[21]  G. Pazour,et al.  Ror2 signaling regulates Golgi structure and transport through IFT20 for tumor invasiveness , 2017, Scientific Reports.

[22]  P. Kirchhof,et al.  2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. , 2016, European heart journal.

[23]  M. Turakhia,et al.  Aspirin Instead of Oral Anticoagulant Prescription in Atrial Fibrillation Patients at Risk for Stroke. , 2016, Journal of the American College of Cardiology.

[24]  T. Chao,et al.  Acute myocardial infarction in patients with atrial fibrillation with a CHA2DS2-VASc score of 0 or 1: a nationwide cohort study. , 2014, Heart rhythm.

[25]  L. Kim,et al.  A guide for the utilization of Health Insurance Review and Assessment Service National Patient Samples , 2014, Epidemiology and health.

[26]  David M Herrington,et al.  Atrial fibrillation and the risk of myocardial infarction. , 2015, JAMA internal medicine.

[27]  J. Piccini,et al.  Warfarin use among older atrial fibrillation patients with non-ST-segment elevation myocardial infarction managed with coronary stenting and dual antiplatelet therapy. , 2013, American Heart Journal.

[28]  L. Køber,et al.  Oral anticoagulation and antiplatelets in atrial fibrillation patients after myocardial infarction and coronary intervention. , 2013, Journal of the American College of Cardiology.

[29]  Leiyu Shi,et al.  Race/Ethnicity, insurance, income and access to care: the influence of health status , 2013, International Journal for Equity in Health.

[30]  M. Borggrefe,et al.  Incidence and Severity of Coronary Artery Disease in Patients with Atrial Fibrillation Undergoing First-Time Coronary Angiography , 2011, PloS one.